Human Genome Sciences (HGSI) Announces Interim Results for ZALBIN Phase 2b on Patients with Hep C
Tweet Send to a Friend
Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced interim results through Week 12 following the end of treatment in a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
